Clinical information of HIFU

Indications for Ablatherm® HIFU

Clinically Localized Prostate Cancer:

  • •First choice therapy (T-1, T-2)
  • •Curative Salvage therapy for local recurrence after EBRT

Ablatherm® HIFU is approved in Canada and has undergone the most extensive research, development and testing. Ablatherm® HIFU is presently being used in England, Belgium, France, Italy, Germany, Russia, South Korea, and other Asian countries.

Histology

histology - 48 hours

48 hours: .

Complete destruction of the glandular tissue due to coagulation necrosis which reaches the capsule and the periprostatic fat.

 


3 months:

The necrotic prostatic tissue is replaced by a fibrotic tissue (including the capsule)

MRI Post-Treatment

MRI of the prostate after an Ablatherm® HIFU session (the whole prostate volume is treated)

 
Transversal plane   Longitudinal plane

MRI examinations performed early after the HIFU treatment of prostate cancer cannot give a qualitative assessment of the necrosis. It does however, allow a precise evaluation of the treated volume as demonstrated in a clinical trial. After gadolinium injection, the treated area appeared as a hypo-intense area and a surrounding 6-8 mm ring of contrast enhancement. Biopsies were taken in the ring, and these also demonstrated complete necrosis in this ring.

Learn more about the HIFU clinical study results

HIFU Research Articles

 

PSA Post-Treatment

Typical PSA evolution after a single treatment session

(complete treatment of the gland)

hifu session PSA post-treatment

  • Elevated PSA level before the treatment of prostate cancer
  • Peak in PSA immediately after the session
  • Nadir PSA obtained 3 months after the treatment
  • Low and stable follow-up PSA level at 0.2 ng/ml

PSA evolution after the first nerve sparing treatment
(need for a second session)

PSA session 2

  • Elevated PSA level before the treatment of prostate cancer
  • Peak in PSA immediately after the first session
  • Nadir PSA obtained within 3 months after the 1st session and showing a residual PSA level
  • Rising PSA level following the Nadir with residual positive biopsies; indication for a 2nd treatment session
  • Then, low and stable follow-up PSA level